Can iCure Escape Delisting? iCure (175250)’s delisting review has been extended, increasing investor anxiety. Despite improved financials and growth in the cosmetics business, the possibility of delisting remains. This article analyzes iCure’s current situation, provides future outlook, and guides investors on the actions they should take. What Happened? On August 27, 2025, iCure announced that … Read more
iCure’s H1 2025 Earnings Surprise… But What’s the Real Story? iCure has released its H1 2025 earnings report. While sales surpassed the expected 0 KRW, the company remains mired in operating and net losses, sending shockwaves through the investor community. What does the future hold for this company? This article analyzes the reasons behind iCure’s … Read more
iCure’s Unexpected Earnings Shock: An Urgent Analysis for Investors iCure’s H1 2025 earnings report sent shockwaves through the market. While revenue showed growth, operating and net income significantly missed expectations, deepening losses. This article provides an in-depth analysis of iCure’s performance and offers a clear investment strategy moving forward. 1. What Happened? iCure’s H1 2025 … Read more
Icure Facing Potential Delisting: Urgent Analysis for Investors Icure’s fate hangs in the balance as the decision on its listing eligibility will be made on August 27th. This is a crucial moment for investors, and the outcome could significantly impact the stock price. This article analyzes Icure’s current situation and outlines key considerations for investors. … Read more